A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma

Journal of Nuclear Medicine

Martina Rudelius¹  Tibor Schuster¹  Markus Schwaiger¹  Christine Scheuerer¹  Ken Herrmann¹  Andreas K. Buck¹  Nicolas Graf¹  Hans-Jürgen Wester¹  Ulrich Keller¹  Tobias Dechow¹  Christian Peschel¹ 

关键词: positron emission tomography;    mantle cell lymphoma;    ¹⁸F-FLT;    ¹⁸F-FDG;   

DOI  :  10.2967/jnumed.111.094698

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma. Proliferation activity is considered an important prognostic marker. Immunohistochemical analysis from core biopsy or lymph node may not represent the proliferation rate. We investigated the in vivo proliferation marker 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) to characterize MCL. Methods: Eight untreated MCL patients were recruited prospectively. 18F-FLT PET/CT was performed 45 min after injection of 18F-FLT. 18F-FDG PET/CT served as reference. Mean 18F-FLT standardized uptake values were assessed per lesion and compared with respective 18F-FDG uptake. Correlation of mean 18F-FLT and 18F-FDG uptake in the hottest lesion to Ki67 immunostaining was performed. Five patients underwent repetitive early 18F-FLT PET. Results: All lymphoma lesions identified by 18F-FDG PET/CT showed increased 18F-FLT uptake. Semiquantitative analysis revealed a high mean 18F-FLT standardized uptake value of 9.9 (range, 5.5–15.9). Mean 18F-FLT uptake and Ki67 expressions showed a strong positive correlation. Conclusion: PET using 18F-FLT as a biomarker for proliferative activity showed a high sensitivity for MCL. 18F-FLT uptake shows a correlation with proliferation. Our results warrant further analysis of 18F-FLT PET in MCL.

【 授权许可】

Unknown